SCHEMBL2809318

SCHEMBL2809318

CCc1cn(CCCOC)c2cc(C(=O)OC)ccc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 1/20 0.45
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 1/20 0.44
GLA P06280 1/20 0.44
GAA P10253 1/20 0.44
PKM P14618 1/20 0.44
HPGD P15428 1/20 0.44
HTT P42858 1/20 0.44
KMT2A Q03164 1/20 0.44
HSD17B10 Q99714 1/20 0.44
CNR1 P21554 3/20 0.41
CNR2 P34972 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
REN P00797 1/20 0.41
TLR7 Q9NYK1 1/20 0.40
PDE4A P27815 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39
HDAC10 Q969S8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2806053 0.86 PDE4A (0.49) SLC22A12KDM4EALDH1A1GLAGAA
SCHEMBL15417986 0.85 REN (0.46) KDM4EALDH1A1GLAGAAPKM
SCHEMBL2813588 0.84 SMN1; SMN2 (0.51) KDM4EALDH1A1GLAGAAPKM
SCHEMBL13131385 0.83 REN (0.40) SLC22A12ALDH1A1CNR1CNR2REN
SCHEMBL13131358 0.81 REN (0.51) SLC22A12ALDH1A1HTTKMT2ACNR1
SCHEMBL13132254 0.80 CNR1 (0.40) SLC22A12ALDH1A1CNR1CNR2REN
SCHEMBL91271 0.80 ICMT (0.54) KDM4EALDH1A1CNR1CNR2REN
SCHEMBL13131410 0.80 MCL1 (0.48) CNR1CNR2RENMCL1
SCHEMBL13131411 0.80 HTR6 (0.40) ALDH1A1CNR1CNR2RENMCL1
SCHEMBL13132252 0.79 PTGER4 (0.45) SLC22A12ALDH1A1HPGDHTTCNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2168952-B1 MORPHOLINE DERIVATIVES AS RENIN INHIBITORS MITSUBISHI TANABE PHARMA CORP (JP) 2017-02-15 EP disclosed
US-8975252-B2 Morpholine derivative SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2015-03-10 US disclosed
US-8975252-B2 Morpholine derivative SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2015-03-10 US disclosed
US-8975252-B2 Morpholine derivative SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2015-03-10 US disclosed
WO-2009055509-A9 CHOLESTEROL CONSENSUS MOTIF OF MEMBRANE PROTEINS THE SCRIPPS RESEARCH INSTITUTE (US) 2010-09-23 WO disclosed
US-20100240644-A1 MORPHOLINE DERIVATIVE SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2010-09-23 US disclosed
US-20100240644-A1 MORPHOLINE DERIVATIVE SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2010-09-23 US disclosed
US-20100240644-A1 MORPHOLINE DERIVATIVE SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2010-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240644-A1 MORPHOLINE DERIVATIVE REN, AGTR1, AGTR2 SLC22A12 2804/4885KDM4E 689/4885ALDH1A1 2202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.